Titan Pharmaceuticals (TTNP) : Gierl Augustine Investment Management Inc added new position in Titan Pharmaceuticals during the most recent quarter end. The investment management firm now holds 2,000 shares of Titan Pharmaceuticals which is valued at $10,560 , the company said in a statement filed on Oct 14, 2016 with the SEC.Titan Pharmaceuticals makes up approximately 0.01% of Gierl Augustine Investment Management Inc’s portfolio.
Other Hedge Funds, Including , Creative Planning sold out all of its stake in TTNP during the most recent quarter. The investment firm sold 5,000 shares of TTNP which is valued $29,550. Cutler Group Lp sold out all of its stake in TTNP during the most recent quarter. The investment firm sold 9 shares of TTNP which is valued $54. Simplex Trading sold out all of its stake in TTNP during the most recent quarter. The investment firm sold 2,019 shares of TTNP which is valued $12,033.
Titan Pharmaceuticals Inc. (Titan) is a specialty pharmaceutical company developing therapeutics for the treatment of medical disorders. The Company’s product development programs utilize its long-term drug delivery platform ProNeura. The Company’s drug candidate Probuphine is being developed for the long term maintenance treatment of opioid dependence. Titan’s ProNeura continuous drug delivery system consists of a small solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. Titan’s drug candidate Probuphine is in Phase III clinical study stage. The Company is also engaged in the development of its ProNeura-Ropinirole product to deliver dopamine agonists for the treatment of Parkinson’s disease. The Company has licensed the rights to commercialize Probuphine in the United States and Canada to Braeburn Pharmaceuticals Sprl (Braeburn).